引文
[1]游利.骨质疏松症的现状、筛查和预防[J].中国全科医学,2016,19(14):1616-1619.
[2]笪巍伟,唐德志,舒冰,等.原发性骨质疏松症及椎体压缩性骨折的防治进展[J].广东医学,2016,37(11):1714-1717.
[3]李春霖.合理应用骨代谢生化标志物,提高骨质疏松患者治疗的依从性[J].标记免疫分析与临床,2015,22(10):943-943.
[4]朱彤彤,黄连弟,李俊玮,等.淫羊藿苷对去卵巢大鼠骨质疏松症的保护作用及其机制[J].吉林大学学报(医学版),2016,42(5):915-919.
[5]刘海龙,卫荣.绝经后骨质疏松症中西医临床治疗进展[J].现代中西医结合杂志,2014,23(14):1594-1596.
[6]刘宗权,宋敏,蒋宜伟,等.淫羊藿苷抗骨质疏松对去势大鼠PINP,NTx影响的实验研究[J].甘肃中医学院学报,2014,31(3):4-7.
[7]祁珊珊,杨祎琦,庞田田,等.去卵巢法建立SD大鼠绝经后骨质疏松模型手术探讨[J].中国兽医杂志,2014,50(2):27-29.
[8]Kaddah E,Elbadrawy A,Mahdi S,et al. Role of vascular endothelial growth factor expression in pathogenesis of postmenopausal osteoporosis[J]. Egyptian Rheumatology&Rehabilitation,2013,40(4):211.
[9]孙伟明,刘爽.雌激素影响绝经后骨质疏松分子机制研究进展[J].中国老年学,2017,37(2):499-502.
[10]高彦彬.中医治疗骨质疏松症[J].中国临床医生杂志,2013,41(6):66-68.
[11]Jia C,Liu H,Li M,et al. Effects of icariin on cytokine-induced ankylosing spondylitis with fibroblastic osteogenesis and its molecular mechanism[J]. International Journal of Clinical&Experimental Pathology,2014,7(12):9104.
[12]刘广飞,程才,王璐,等.淫羊藿苷治疗骨质疏松的研究进展[J].现代生物医学进展,2015,15(26):5185-5188.
[13]Liu M,Zhong C,He R X,et al. Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis[J]. Chin Med J,2012,125(10):1784.
[14]吴祖锋,袁垒,吴风晴,等.淫羊藿苷对骨质疏松症模型大鼠OPG/RANKL/RANK轴系统影响的实验研究[J].甘肃中医学院学报,2016,33(3):4-7.
[15]魏双双,张治芬,黄哲人,等.雌激素对去卵巢大鼠骨组织Wnt16、β-catenin、OPG、RANKL表达的影响[J].浙江医学,2017,39(4):245-249.